Results 101 to 110 of about 27,286 (175)

Correction: Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer

open access: yes
<jats:p>Correction for ‘Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer’ by Yuejie Zhu <jats:italic>et al.</jats:italic>, <jats:italic>RSC Med.
Xu, Bo   +9 more
core   +1 more source

An intelligent poly aptamer-encoded DNA nanoclew for tumor site activated mitochondria-targeted photodynamic therapy and MR imaging

open access: yesMaterials Today Bio
Mitochondria-targeted photodynamic therapy (PDT) has emerged as one of the most promising antitumor therapies, as it significantly enhances the efficacy of photosensitizers. An efficient and biocompatible nanocarrier to deliver cationic photosensitizers (
Minghui Chen   +7 more
doaj   +1 more source

Simple PEG Modification of DNA Aptamer Based on Copper Ion Coordination for Tumor Targeting. [PDF]

open access: yes, 2011
A simple modification of a DNA aptamer with poly(ethylene glycol) (PEG) based on metal coordination was developed. N, N-bis(carboxymethyl)-L-lysine (NTA) of a metal chelate residue was chemically introduced to one terminus of PEG. The NTA-introduced PEG (
Jo, Jun-Ichiro   +2 more
core  

Facile Strategy To Enhance Specificity and Sensitivity of Molecular Beacons by an Aptamer-Functionalized Delivery Vector

open access: yes, 2019
To enhance the specificity and sensitivity of molecular beacons (MBs) in detecting mRNA in living tumor cells, we introduced an aptamer (AS1411) to the delivery system of MBs to form an aptamer-decorated nanoprobe (ANP), which was prepared through self ...
Si-Xue Cheng (1604158)   +5 more
core   +1 more source

Synthesis and Evaluation of AS1411-Lenalidomide-Targeted Degradation Chimera in Antitumor Therapy

open access: yesPharmaceuticals
Background: High expression of nucleolin (NCL) on the surface of tumor cells is closely associated with disease progression and poor prognosis. The aptamer–PROTAC conjugate (APC) technology provides a novel molecular design strategy for the targeted ...
Xueling Ma   +11 more
doaj   +1 more source

Extracellular Vesicle‐Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood‐Tumour Barrier Formation

open access: yesJournal of Extracellular Vesicles
Glioblastoma (GBM) remains a significant therapeutic challenge. While GBM‐derived extracellular vesicles (EVs) are known to remodel the normal blood‐brain barrier (BBB) into a blood‐tumour barrier (BTB), the underlying mechanism is largely not understood.
Hongzhen Chen   +7 more
doaj   +1 more source

Formulation optimization of lyophilized aptamer-gold nanoparticles: Maintained colloidal stability and cellular uptake

open access: yesHeliyon
Anti-nucleolin (NCL) aptamer AS1411 is the first anticancer aptamer tested in clinical trials. Gold nanoparticles (AuNP) have been widely exploited for various biomedical applications due to their unique functional properties. In this study, we evaluated
Dalya Saidi   +9 more
doaj   +1 more source

Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release

open access: yesJournal of Translational Medicine
Background Triple-negative breast cancer (TNBC) is a recurrent, heterogeneous, and invasive form of breast cancer. The treatment of TNBC patients with paclitaxel and fluorouracil in a sequential manner has shown promising outcomes.
Yuan Ma   +10 more
doaj   +1 more source

Selective Delivery of an Anticancer Drug with Aptamer-functionalized Liposomes to Breast Cancer Cells in vitro and in vivo

open access: yes
Selective targeting of cancer cells is a critical step in cancer diagnosis and therapy. To address this need, DNA aptamers have attracted significant attention as possible targeting ligands. However, while their use in targeting cancer cells in vitro has
Tang, Li   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy